of our members each and
|
|
- Arron Campbell
- 5 years ago
- Views:
Transcription
1 s p e c i a l t y d r u g n e w s Positively affecting the lives of our members each and every day Efalizumab (Raptiva ) Withdrawn from US Market On April 9, 2009 Genentech, Inc. announced that it is undergoing a voluntary, phased withdrawal in US markets of Raptiva, due to the potential risk to patient of developing progressive multifocal leukoencephalopathy (PML). Efalizumab is used for treatment of chronic moderate or severe plaque psoriasis. PML is a rare and usually fatal viral disease characterized by progressive damage or inflammation to the white ma er of the brain at multiple locations. According to the FDA the risk that an individual patient taking efalizumab will develop PML is rare and is generally associated with long-term use. PML generally occurs in patients with immune systems that are severely weakened and o en leads to an irreversible decline in neurologic function and death. Efalizumab will no longer be available in the United States a er June 8, 2009, and healthcare providers are being asked not to initiate treatment in new patients. Physicians are also being asked to closely monitor patients who have been on the therapy for any sign or symptom that is suggestive of PML and for infections or other adverse events a er stopping treatment. FDA Grants Fast-Track Status for Multiple Sclerosis Drug Teva Pharmaceuticals has announced that the FDA has granted fast-track review status of oral laquinimod for treatment of multiple sclerosis. This designation should help expedite its future review by the FDA a er results of the current clinical trials are reviewed. MS occurs when the immune system mistakenly a acks the myelin sheath on nerve fibers, and also damages other brain and spinal cord tissues. Laquinimod is believed to affect this immune a ack. Laquinimod reduced disease activity by 40.4% compared to inactive placebo in earlier phase 2 studies. Volume 19 April 2009 In this issue: Efalizumab (Raptiva) Withdrawn from US Market FDA Grants Fast- Track Status for Multiple Sclerosis Drug Benchmarking Survey Shows Treating Patients in the Office with Specialty Drugs is Critical to Rheumatologists Revenue Streams 1st Quarter 2009 Speciatly Drug Pipeline Specialty Drug Listing Currently, the Allegro study, a phase 3 study of laquinimod versus inactive placebo in 1000 participants with relapsing-remi ing MS, is underway. A second phase 3 study, the Bravo study, of laquinimod in comparison to inactive placebo or Avonex is underway in 1200 participants.
2 Benchmarking Survey Shows Treating Patients in the Office with Specialty Drugs is Critical to Rheumatologists Revenue Streams A recent report from Onmark, a leading national group purchasing organization for community based-medical practices and a McKesson Specialty Care Solutions company, shows that rheumatologists rely on specialty drugs like Remicade for revenue streams. In a survey that measures operational and financial benchmarks to help practices improve business operations, efficiency and quality of care the following data was collected in 2007: General practice information Accounts receivable and general revenue data Operating costs Ancillary services Compensation The survey revealed that the sale and administration of drugs to patients represents 74% of the revenue of the practices surveyed. The total cost of drugs for in-office administration to patients accounts for an average of 62% of all practice expenses. The total average drug costs per practice is about $4,875,796, subtracting all rebates and excluding medications sold to patients for home use. The most commonly coded procedures from rheumatology offices are related to drug administration. *Source: Business Wire Drug Name RiaSTAP Atryn Promacta fludarabine Treanda Degarelix Mozobil SPECIALTY PIPELINE UPDATE Indication for Use Used in treating acute bleeding episodes in patients with congenital fibrinogen deficiency Prevention of thromboembolic events thrombocytopenia in patients with chronic ITP adults with relapsed or refractory B-cell CLL B-cell non-hodgkin's lymphoma advanced prostate cancer Used to mobilize stem cells for collection and autologous transplants in patients with NHL and mutiple myeloma Route of Approval Date Contact: For more information regarding LDI s Specialty Newsle er, please contact us: (314) x189 (866) x189 VBohn@LDIRx.com IV injection 1/16/09 First approved treatment for this indication IV injection 2/6/09 First approved biological prodcut produced by genetically engineered animals 11/20/08 First oral thrombopoietin receptor agonist approved for adults with chronic ITP 12/18/08 10/31/08 Previously approved for treatment of CLL 12/24/08 12/15/08 Potential to decrease number of apheresis days required to collect cells for transplant
3 PIPELINE MEDICATIONS IN PHASE III TRIALS Drug Name Indication for Use Route of Kiacta Hematide Bosatria amyloid A amyloidosis anemia in patients with chronic renal failure hypereosinophilic syndrome Injection Administered once every four weeks in clinical trials Denufosol cystic fibrosis Inhalation Orphan drug with fast track status. Primary endpoints achieved in first phase III trial in June 2008 prgcd (plant cell expressed recombinant glucocerebrosidase Gaucher disease Enrollment complete for phase III trial Velaglucerase alfa Albuferon Boceprevir Berinert P DX-88 (ecallantide) Rhucin Vicriviroc Tesamorelin Corifollitropin alfa Golimumab Ustekinumab Canakinumab type 1 Gaucher disease In combination with ribavirin for treatment of chronic hepatitis C In combination with Peg-Intron and Rebetol for treatment of hepatitis C acute a acks in patients with hereditary angioedema (HAE) moderate to severe acute HAE a acks acute a acks in patients with HAE HIV in combination with other antiretroviral agents HIV-associated lipodystrophy Worldwide enrollment for phase III trial completed Injection Phase III data expected by spring 2009 Enrollment complete for phase III trial with fast track status Two large phase III trials Infertility Primary endpoints met in phase III trial RA, psoriatic arthritis and ankylosing spondylitis Treatment in adults with chronic moderate to severe plaque psoriasis cryopyrin-associated syndromes
4 PIPELINE MEDICATIONS IN PHASE III TRIALS, continued Drug Name Indication for Use Route of Actemra Pegloticase Fampridine-SR Dirucotide Fingolimod Teriflunomide Laquinimod Pasireotide Zactima Opaxio Pixantrone Used in reducing signs and symptoms in adults with moderate to severe RA gout in patients for whom conventional treatment is contraindicted or ineffective Use to treat walking ability in patients with MS secondary-progressive MS relapsing-remitting MS relapsing forms of MS relapsing-remitting MS Cushing's disease and acromegaly Second line treatment of nonsmall cell lung cancer advanced nonsmall cell lung cancer in women and for maintenance treatment of ovarian cancer relapsed non- Hodgkin's lymphoma Lestaurtinib acute myeloid leukemia Provenge metastatic hormone-refractory prostate cancer Ceplene In conjunction with IL-2 as a remission maintenance treatment of AML Arzerra refractory CLL Genasense relapsed or refactory CLL Virulizin First-line treatment of pancreatic Intramuscular cancer in combination injection with Gemzar FDA has requested additional information, including a proposal for a Risk Evaluation and Mitigation Strategy FDA granted priority review status in December 2008 FDA granted fast track status Also being studied in combination with interferon-beta and Copaxone Phase III trial enrollment complete November 2008 FDA granted fast track status Designed to reduce the potential for heart damage compared to current anthracyclines FDA final analysis expected mid-2009 with fast track status
5 PIPELINE MEDICATIONS IN PHASE III TRIALS, continued Drug Name Indication for Use Route of Phenoxodiol hormonerefactory IV injection/oral FDA granted fast track status prostate cancer in Taxotere nonresponders and recurrent chemo resistant late-stage ovarian cancer Deforolimus metastatic sarcoma Afinitor advanced renal FDA granted priority review status cell carcinoma and neuroendocrine tumors Trabectedin In combination with Doxil for treatment of relapsed ovarian cancer Larotaxel Second-line treatment of pancreatic cancer Denosumab postmenopausal osteoporosis and cancer-related bone loss Thelin pulmonary arterial hypertension. Phase III study initiated in November 2008 Pirfenidone idiopathic pulmonary fibrosis Numax RSV IM injection Expected to be more potent than Synagis. FDA has requested more information. Certican Prevention of solid organ rejection in combination with Neoral Clinical trials ongoing NEW DOSAGE FORMS IN THE PIPELINE Drug Name Current Indication Investigational Indication Xolair Cinryze moderate to severe persistent allergic asthma (age 12 and above) Routine prophylaxis against angioedema a acks in patients with HAE children 6 years and above with moderate to severe persistent allergic asthma acute angioedema a acks in patients with HAE Route of FDA granted priority review status in February 2009
6 NEW DOSAGE FORMS IN THE PIPELINE, continued Drug Name Current Indication Investigational Indication Isentress H.P. Acthar Gel Orencia Rituxan In combination with other antiretroviral agents for treatment-experienced HIV patients who have evidence of viral replication and HIV strains resistant to multiple antiretroviral agents Multiple indications, including the diagnostic testing of adrenocortical function and the treatment of MS exacerbations moderately to severely active RA in adults and moderately to severe active polyarticular juvenile idiopathic arthritis in pediatric patients 6 years of age and older non-hodgkin's lymphoma and treatment of moderately to severely active RA in patients who have had an inadequate response to one or more TNF inhibitors In combination with other antiretroviral agents for patients with treatment-naïve HIV For treatment of infantile spasms patients with early RA moderately to severely active RA in patients who have had an inadequate response to prior treatment with a diseases modifying anti-rheumatic drug Cimzia Crohn's disease moderate to severe or active RA Zevalin relapsed or refractory, low-grade or follicular B-cell NHL Consolidation therapy for patients with follicular B- cell NHL who achieve a response to firstline therapy Route of IM or IV injection FDA response to supplemental new expected July 2009 resubmitted December 2008 filed in the fourth quarter 2008 filed October 2008 FDA has requested a new safety update with all clinical data FDA granted priority review status December 2008
7 NEW DOSAGE FORMS IN THE PIPELINE, continued Drug Name Current Indication Investigational Indication Avastin Clolar Tasigna Sutent Forteo Reclast breast cancer, colorectal cancer and nonsmall cell lung cancer pediatric patients (1 to 21 years old) with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens chronic and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia GIST and advanced RCC men and postmenopausal women with osteoporosis who are at high risk for fracture Paget's disease and postmenopausal osteoporosis First line treatment of renal cell carcinoma (in combination with interferon alfa-2a) and for treatment of relapsed glioblastoma multiforme adult patients with AML gastrointestinal stromal tumor (GIST) in patients who have failed both Gleevec and Sutent colorectal cancer, metastatic breast cancer and non-small cell lung cancer glucocorticoidinduced osteoporosis glucocorticoidinduced osteoporosis Route of Responses to supplemental new drug applications expected in May 2009 for glioblastoma and August 2009 for RCC drug filing expected in 2009 Phase III trials ongoing filed 2008
8 NEW DOSAGE FORMS IN THE PIPELINE Drug Name Indication Current Route of Investigational Route of C2L (octreotide) Cayston TBM 100 (tobramycin) Mylinax Trelstar Viveta acromegaly patients with cystic fibrosis who have pulmonary Pseudomonas aeruginosa patients with cystic fibrosis who have pulmonary Pseudomonas aeruginosa relapsing forms of MS For palliative treatment of advanced prostate cancer pulmonary arterial hypertension IM injection IM injection Prolonged release formulation designed to be dosed less frequently than the long-acting formulation (Sandostatin LAR) IV injection Inhalation. Available through expanded access program. Solution for inhalation Powder for inhalation Expected to provide rapid convenient administration of tobramycin. with fast track status IM Injection IM Injection This formulation is a sustainedrelease formulation designed to be administered every six months. SC or IV Inhalation Studied in combination with Tracleer infusion or Revatio
9 Specialty drug listing AIDS/HIV Daunoxome Doxil Intron A Roferon-A Serostim Taxol Fuzeon Alpha1 - Proteinase Inhibitor Deficiency Aralast Prolastin Zemaira Antihemophilic Agents Antihemophilic Factor Advate Alphanate Bioclate Helixate FS Hemofil M Humate P Hyate C Koate DVI Kogenate FS Monarc M Monoclate P Recombinate ReFacto Anti-nausea Aloxi Anzemet Emend Kytril Zofran Asthma Xolair Cancer/Related Adriamycin Adrucil Alkeran Aredia Avastin BiCNU Blenoxane Busulfex Campath Camptosar Cerubidine Cosmegen Cytarabine Cytoxan Depocyt Doxil DTIC-Dome Eligard Ellence Erbitux Ethyol Faslodex Fludara Gemzar Gleevec Herceptin Hycamtin Idamycin IFEX Intron A Leucovorin Leukine Leustatin Lupron Depot Lupron Depot-Ped Mesnex Mustargen Mutamycin Mylotarg Navelbine Nexavar Nipent Novantrone Oncaspar Ontak Paraplatin Platinol AQ Proleukin Rituxan Roferon-A Sutent Tarceva Taxol Taxotere Temodar Thyrogen Toposar Trelstar Depot Trelstar LA Trisenox VePesid Vinblastine Vincasar Vumon Xeloda Zanosar Zoladex Zometa Contraceptives Depo-Provera Crohn s Disease Remicade Dystonia Botox Myobloc Factor IX Concentrates Alphanine SD Benefix Mononine Profilnine SD Proplex T Bebulin VH Gaucher s Disease Ceredase Cerezyme Zavesca Growth Hormone Deficiency Genotropin Humatrope Norditropin Nutropin Nutropin AQ Saizen Hematologics Arixtra Aranesp Epogen Fragmin Innohep Lovenox Neulasta Neumega Neupogen Procrit Hepatitis C Copegus Infergen Intron A Pegasys Peg-Intron Rebetron Roferon-A Hormone Deficiency Delatestryl Delestrogen Depo-Estradiol Depo-Testosterone Hunter Syndrome Elaprase Primary Immunodeficiency Carimune NF Gamimune N Gammagard S/D Gammar-P Gamunex Iveegam EN Panglobulin Panglobulin NF Polygam S/D Venoglobulin-S Miscellaneous Alferon-N Milrinone Zinecard Multiple Sclerosis Avonex Betaseron Copaxone Novantrone Rebif Tysabri Osteo/ Rheumatoid/ Psoriatic Arthritis Enbrel Humira Hyalgan Kineret Orencia Remicade Supartz Synvisc Osteoporosis Forteo Miacalcin Psoriasis Amevive Enbrel Raptiva Remicade Respiritory Syncytial Virus Synagis Rh Hemolytic Disease BayRho-D Micro-Rhogam Rhogam WinRho-SDF
Positively Affecting the Lives of Members Each and Every Day. Volume 14 May Specialty Drug News
Positively Affecting the Lives of Members Each and Every Day LDI Volume 14 May 2008 Specialty Drug News 2008 Medications to Watch 1. Respiratory syncytial virus (RSV) Numax (motavizumab) Respiratory syncytial
More informationRAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)
INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193
More informationSPECIALTY PHARMACY Master Clinical Drug List
Abraxane J9264 Provider ONCOLOGY None NO Actemra J3262 Provider ARTHRITIS PA - all YES Acthar HP Gel J0800 Prov/Self Med/Pharm ENDOCRINE/METABOLIC PA - all YES Adagen J2504 Provider ENZYME DISORDERS None
More informationPharmacy and Medical Guideline Updates
STAT Bulletin PO Box 15013 Albany, New York 12212 August 2, 2010 Volume 8: Issue 19 To: All PCPs and Specialists Contracts Affected: All Lines of Business Pharmacy and ical Guideline Updates As a result
More informationDrug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
More informationAetna Better Health. Specialty Drug Program
Aetna Better Health is managed through CVS Health Specialty Pharmacy. The Specialty pharmacies fill prescriptions and ship drugs for complex medical conditions, including multiple sclerosis, rheumatoid
More informationSpecialty Pharmacy Pipeline Report
Specialty Pharmacy Pipeline Report Fourth Quarter 2008 To help keep you informed about medications in development, the Walgreens Specialty Pharmacy Pipeline Report provides a summary of specialty medications
More informationProvider Administered Drug Program (PADP) and Physician Administered Drug VPSS List
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea
More informationSpecialty conditions overview
Specialty conditions overview Prevalence and cost Click on the vials to learn more about these specialty conditions. 1. Approximate annual AWP cost per patient of top utilized drugs for UHC calendar year
More informationPrescription Drug Benefit Rider V
Prescription Drug Benefit Rider V Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More informationPrescription Drug Benefit Rider
Prescription Drug Benefit Rider Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More informationPrior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD
Abatacept (Orencia) 1, 2, 7, 11, 13, 14, 18, 24, 31, 44, 48, 49, 51, 53, 55, 57 J0129 Alpha 1 - Proteinase inhibitor (Prolastin-C) 5, 6, 10, 12, 40 Medically Necessary (if all the following criteria apply):
More informationBCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015
Prior Authorization List 2015 Participating providers are responsible to furnish or arrange health care services with other participating healthcare facilities or providers. Prior authorization requests
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationSTAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 9: Issue 27 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
More informationSpecialty Pharmacy Pipeline Report
Specialty Pharmacy Pipeline Report Third Quarter 2008 To help keep you informed about medications in development, the Walgreens Specialty Pharmacy Pipeline Report provides a summary of specialty medications
More informationSection I contains changes to the Highmark Select/Choice Formulary.
March 2008 1 st Quarter Update: Highmark Drug Formulary Enclosed is the 1 st Quarter 2008 update to the Highmark Drug Formulary and pharmaceutical management procedures. The Formulary and pharmaceutical
More informationOriginal Policy Date
MP 5.01.17 Specialty Drugs Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/ Date Local policy Last updated/12:2013 Return to Medical Policy Index
More informationSpecialty Pharmacy Pipeline Report
Specialty Pharmacy Pipeline Report Fourth Quarter 2009 To help keep you informed about medications in development, the Walgreens Specialty Pharmacy Pipeline Report provides a summary of specialty medications
More informationLDI integrated pharmacy services
8 ARRANON CARIMUNE NF Immunodeficiency 8-MOP Psoriasis ARZERRA CAYSTON Cystic Fibrosis A ASTAGRAF XL Antirejection CERDELGA Gaucher's Disease abacavir ATRIPLA CEREZYME Gaucher's Disease abacavir/lamivudine/
More informationTo help doctors give their patients the best possible care, the American
Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationPRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
More informationInjectable Drugs Requiring Pre-Service Approval
Abatacept Orencia J0129, 10 mg 1500 FL LCD- L29051 1) For patients with rheumatoid arthritis with failure, intolerance or contraindications to methotrexate. Limit dosing to 40 mg Q 2 weeks. 2) For patients
More informationList of Designated High-Cost Drugs
List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at
More informationMagellan Rx. A smarter approach to pharmacy benefits management
Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We
More information2010 Drugs Requiring Prior Authorization
2010 Drugs Requiring Prior Authorization Drugs Covered Uses Exclusion Criteria Actemra (tocilizumab) Adcirca (tadalafil) Alfa Interferons - Alferon N - Infergen - PEG-Intron - PEG-Intron Redipen - Pegasys
More informationHCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1
drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A
More informationUNDERWRITING GUIDE. Secure Advantage HOSPITAL COVERAGE. The Insurance Policy That Pays You Cash In The Event Of A Covered Hospitalization
UNDERWRITING GUIDE Secure Advantage HOSPITAL COVERAGE The Insurance Policy That Pays You Cash In The Event Of A Covered Hospitalization TABLE OF CONTENTS Contents Page Secure Advantage Underwriting Guide...2
More informationNew Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009
STAT Bulletin PO Box 80 Buffalo, New York 14240-0080 May 12, 2009 Volume 15:Issue 18 To: All Home Health Care and Home Infusion Therapy Providers Contracts Effected: All Lines of Business New Billing Guidelines
More informationDescriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin
Self-Administered Drug Exclusion List R2 This article from Medicare A News, Issue 2106 dated January 23, 2013 and Medicare B News, Issue 283 dated January 23, 2013 is being revised to add Acthar ACTH gel
More informationAcute Lymphocytic Leukemia
Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin
More informationMedStar Medicare Choice Pharmacy Services
Pharmacy Services 1 MedStar Medicare Choice Pharmacy Services Table of Contents At a Glance..page 2 Pharmacy Policies..page 4 Medicare Choice Pharmacy Programs..page 6 Where to Obtain Prescriptions..page
More informationPharmacy Services Request Types
FOR DRUG REQUESTS, ONLY-- * NOTE: Only those drugs administered by a healthcare provider and billed medically would be entered via CareAffiliate. * Oral drugs would not be administered by a healthcare
More informationIntron A. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Page: 1 of 6 Last Review Date: June 19, 2015 Intron A Description Intron A (interferon
More informationSelf-Injected Medications and Disposal Recommendations
Actimmune (interferon gamma 1b) Apokyn (apomorphine hydrochloride) Arixtra (fondaparinux) Avonex (interferon beta 1a) Betaseron (interferon beta 1b) Copaxone (glatiramer acetate) Edex (alprostadil) InterMune
More informationDirectorate General of Health Services Office of Drugs Controller General (India) (Biological Division)
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) List of r-dna drug products approved in the country (Form 45 and 45A) from 1 st Jan 2015 to 30 th
More informationEquiCash UNDERWRITING GUIDE. Equitable &You. The Policy That Pays You Cash In The Event You Have To Be Hospitalized HOSPITAL PLAN
UNDERWRITING GUIDE EquiCash HOSPITAL PLAN The Policy That Pays You Cash In The Event You Have To Be Hospitalized Rev. 10/13 Equitable &You... Committed To Caring TABLE OF CONTENTS Contents Page EquiCash
More informationHMSA Pharmacy Newsletter April 2006 For Participating Medical Practitioners
For Participating Medical Practitioners CDC HEALTH ALERT - USE OF ANTIVIRALS FOR INFLUENZA The U.S. Centers for Disease Control and Prevention (CDC) issued a Health Alert on January 14, 2006 regarding
More informationPRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
More informationNew Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications
Q4 2017 Advair Diskus salmeterol Asthma, COPD inhaler Advair HFA salmeterol Asthma inhaler Airduo Respiclick salmeterol Asthma inhaler Alecensa alectinib Non-Small Cell Lung Cancer Genentech announced
More informationBrand Generic J-Code 1 Billable. Exclusion Criteria. Information and Criteria. Unit
Affinity Health Plan Department Of Pharmacy (Medicaid, Child Health Plus, Family Health Plus, Medicare Part B) **Medications Requiring Authorization under Medical Benefit** Click Here For Medication Authorization
More informationSPECIALTY PHARMACY PIPELINE REPORT
SPECIALTY PHARMACY PIPELINE REPORT First Quarter 2010 To help keep you informed about medications in development, the Walgreens Specialty Pharmacy Pipeline Report provides a summary of specialty medications
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),
More informationCHAPTER 7 SECTION 7.1 DRUGS AND MEDICINES TRICARE/CHAMPUS POLICY MANUAL M DEC 1998 OTHER SERVICES
TRICARE/CHAMPUS POLICY MANUAL 6010.47-M DEC 1998 OTHER SERVICES CHAPTER 7 SECTION 7.1 Issue Date: December 29, 1982 Authority: 32 CFR 199.4(b)(2)(v), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), and (e)(11)(i)
More information2014 AlohaCare Advantage (HMO) and AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Prior Authorization Requirements
2014 AlohaCare Advantage (HMO) and AlohaCare Advantage Plus Formulary (HMO SNP) with Prior Authorization Requirements You may need prior authorization for certain drugs that are on the formulary or drugs
More informationBLOOD AND LYMPH CANCERS
BLOOD AND LYMPH CANCERS 2 Blood and Lymph Cancers Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Kenneth C. Anderson, MD Harvard Medical School and Dana-Farber
More informationDrugs That Require Prior Authorization (PA) Before Being Approved for Coverage
Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage You will need authorization by your UA Medicare Part D Prescription Drug Plan before filling prescriptions for the drugs shown
More informationIssue Date: December 29, 1982 Authority: 32 CFR 199.4(b)(2)(v), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), and (e)(11)(i)
TRICARE/CHAMPUS POLICY MANUAL 6010.47-M DEC 1998 OTHER SERVICES CHAPTER 7 SECTION 7.1 Issue Date: December 29, 1982 Authority: 32 CFR 199.4(b)(2)(v), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), and (e)(11)(i)
More informationAdvantage by Peach State Health Plan 2012 Prior Authorization Listing. Approved 10/23/2011 Effective October 2011
Advantage by Peach State Health Plan 2012 Approved 10/23/2011 Effective October 2011 Note to members: The prior authorization requirements are listed to provide you with information to discuss treatment
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
More informationPrior Authorization Program
Prescription Drug List January 2011 Prior Authorization Program The prior authorization program helps us offer broad prescription drug coverage and promotes safe, clinically appropriate drug usage. Under
More informationMedication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationChemotherapy 101 for Radiation Oncology Workers
Chemotherapy 101 for Radiation Oncology Workers James Sinclair, M.D. CCARE/Medical Director Scripps Cancer Center March 9, 2013 Category 1) Alkylating agents Alkylating agents directly damage DNA to prevent
More informationUtilization Management
Abraxane Abraxane Actemra (IV) Inflammatory Conditions PA/Step Actemra (SQ) Inflammatory Conditions PA/Step Acthar HP Miscellaneous CNS Disorders PA Actimmune NF Adcetris Adcirca Adempas Advate (all forms)
More informationLIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT
LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT The following medications may be covered under your medical benefit if they are provided to you in your doctor s office or outpatient infusion
More informationHMSA Pharmacy Newsletter February
HMSA s HMSA Pharmacy Newsletter February 2006 www.hmsa.com/portal/provider CDC HEALTH ALERT - USE OF ANTIVIRALS FOR INFLUENZA The U.S. Centers for Disease Control and Prevention (CDC) issued a Health Alert
More informationNEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973)
NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) 467-6800 Investor: Karl Mahler 011 41 61 687 8503 Thomas Kudsk Larsen (973) 235-3655 Biogen Idec Contacts: Media: Christina Chan (781) 464-3260
More informationMedication Prior Authorization Form
Section I Member Information Name (Last, First, Middle Initial) Date of Birth WEA Trust Subscriber Number Diagnosis Page 2 1. MEDICATION 2. STRENGTH 3. DIRECTIONS 4. QUANTITY FEIBA NF NovoSeven RT HEMOFIL
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More informationafter reconstitution No Yes Refrigerate; do Not freeze. Discard unused portions; do Not save for further Immune Deficiencies & Related
Store at room temp. Protect from bright light. Freezing or refrigerating do not adversely affect the stability of intact vials. Different standards apply Abraxane Oncology- Injectable IV No No Yes after
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationMedication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication
More informationOncology Market Opportunities, Strategies, and Forecasts, 2006 to Oncology. Picture by Susie Eustis MOUNTAINS OF OPPORTUNITY
Oncology Market Opportunities, Strategies, and Forecasts, 2006 to 2012 Oncology Picture by Susie Eustis MOUNTAINS OF OPPORTUNITY WinterGreen Research, Inc. Lexington, Massachusetts www.wintergreenresearch.com
More informationForm 2023 R2.0: Ovarian Cancer Pre-HSCT Data
Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationIntron A. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.07 Subject: Intron A Page: 1 of 6 Last Review Date: June 24, 2016 Intron A Description Intron A (interferon
More informationFor peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation
Last Review: 4/2010 NON-FORMULARY Clinical Guideline Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF), Neumega (oprelvekin; rh-il-11), Leukine (sargramostim; GM-CSF) Indications Neupogen
More informationOvarian Cancer. compendia TREATMENT OF
drug & compendia TREATMENT OF Ovarian Cancer With each publication, ManagedCare Oncology s drug & Compendia highlights a single medication or a group of medications that could be utilized in the management
More informationHodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data
Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Research ID: Event date: / / Visit 100 day 6 months 1 year 2 years
More informationMULTIPLE SCLEROSIS - REVIEW AND UPDATE
MULTIPLE SCLEROSIS - REVIEW AND UPDATE Luka Vlahovic, MD Neuroimmunology/Multiple Sclerosis Creighton University Medical Center MS is primary demyelinating disease of the central nervous system. MS is
More informationHEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
More informationMedical Coverage Guidelines are subject to change as new information becomes available.
ENBREL (etanercept) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationSpecialty Overview by Prior Authorization Approval or Denial 2nd Quarter 2016
Specialty Overview by Prior Authorization Approval or 2nd Quarter 2016 3961 DERMATOLOGY Humira RHEUMATOID ARTHRITIS Approval Approved from 04/13/2016 thru 04/13/2018 3961 DERMATOLOGY Stelara PSORIASIS
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017
More informationINJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions
J9190 5-FU fluorouracil None. J0401 ABILIFY MAINTENA aripiprazole i.v. J9264 ABRAXANE paclitaxel protein bound J3262 ACTEMRA IV tocilizumab Yes, through Navitus. Restricted to (in at least consultation
More informationList 1 PRESCRIPTION DRUGS REQUIRING PRE-AUTHORIZATION LIBERTY HEALTH DRUG IDENTIFICATION NUMBER (DIN)
PRESCRIPTION DRUGS REQUIRING PRE-AUTHORIZATION List 1 ACNE THERAPY If covered person over 30 years of age approval by Liberty Health required RETIN A CR 0.01% 00897329 RETIN A CR 0.025% 00897310 RETIN
More informationRituxan (rituximab) DRUG POLICY BENEFIT APPLICATION
DRUG POLICY BENEFIT APPLICATION Rituxan (rituximab) Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationSTAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 17: Issue 34 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
More informationChanges from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationMETABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST
PRIOR AUTHORIZATION LIST (SUBJECT TO CHANGE) MEDICATION THERAPEUTIC CATEGORY MODULE ACTEMRA INFLAMMATORY CONDITIONS ACTEMRA ADCIRCA PULMONARY HYPERTENSION PDE-5 INHIBITORS FOR PAH ADDYI SEXUAL DISORDERS
More informationMDwise Self-Administered Codes for Medical
The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively
More informationMultiple Sclerosis , The Patient Education Institute, Inc. nr Last reviewed: 04/17/2017 1
Multiple Sclerosis Introduction Multiple sclerosis, or MS, is a disease of the brain and spinal cord. Most patients with multiple sclerosis are able to lead a very functional life. However, MS causes a
More informationSpecialty Pharmacy Pipeline Report
Specialty Pharmacy Pipeline Report Third Quarter 2007 To help keep you informed about medications in development, the Walgreens Specialty Pharmacy Pipeline Report provides a summary of specialty medications
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationMDwise HIP Prior Authorization and Drug List
MDwise HIP Prior Authorization and Drug List Services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services With the exception of ER, Ambulance, Urgent Care Center
More informationInfergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.04 Subject: Infergen with Ribavirin Page: 1 of 8 Last Review Date: March 13, 2014 Infergen with Ribavirin
More informationCase Study: Physician and Patient-Facing Medical Education APPs. Sandeep Pulim, MD Chief Medical Information Officer
Case Study: Physician and Patient-Facing Medical Education APPs Sandeep Pulim, MD Chief Medical Information Officer Quality IME Collaborating for Patient Care Commercial Supporter Medical Education Provider
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationAnticipated Launches Q Q1 2019
Anticipated Launches Q4 2018-Q1 2019 Disease Prevalence Amyloidosis Tegsedi (inotersen) subcutaneous (SC) injection Akcea s/ionis Pharmaceuticals hereditary transthyretin amyloidosis (hattr) with polyneuropathy,
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More information